Curious cases of financial engineering in biotech (32 minute read)
Financial engineering in biotech is making drug development failure more survivable through portfolio diversification, synthetic royalties, and even liquidation markets for failed companies, but may be reshaping what kinds of medicines get funded.
What: An exploration of financial structures transforming drug development, including portfolio companies that bundle multiple drug programs to survive individual failures (BridgeBio, Roivant), manufactured royalty agreements on future drug sales, priority review vouchers that create perverse incentives, and vulture investors buying failed biotechs to sell their assets piecemeal.
Why it matters: As R&D costs climb and success rates fall, these financial innovations increasingly determine what gets funded—the concern is that capital may flow toward "legible" opportunities like rare diseases with clear economics rather than high-risk work that could produce transformational medicines like GLP-1s, while synthetic royalties mean more drug revenue goes to financial intermediaries before reaching patients.
Takeaway: If you're building a biotech, familiarize yourself with hub-and-spoke models, synthetic royalty structures, and CVR mechanics—these determine your funding options and may be your only path to survival in tight capital markets.
Deep dive
- Andrew Lo's 2012 thesis argued bundling 50+ uncorrelated drug programs with $5-15B funding makes individual 95% failure rates survivable—if one hits, it pays for all failures, turning terrible individual bets into sound portfolio math
- BridgeBio and Roivant implemented this as hub-and-spoke models where subsidiary companies each pursue one drug, failures die without killing the parent, but Centessa's attempt failed and they pivoted to single-asset focus after market crash
- BridgeBio's stock dropped 72% when lead drug acoramidis failed primary endpoint, proving markets don't actually believe in portfolio diversification theory—though the drug later succeeded on secondary endpoints and got approved as Attruby
- The bond-market component of Lo's vision never materialized because biotech lacks institutional infrastructure like a Moody's for drug risk assessment or Fannie Mae equivalent to securitize biopharma loans for pension funds
- Royalty Pharma pioneered buying drug royalty streams from universities and small biotechs, creating $2.38B in annual revenue from what is essentially a filing cabinet of contractual claims on approved drugs
- Synthetic royalties are manufactured financial obligations where biotechs sell a percentage of future drug sales that didn't previously exist, growing 33% annually and reaching $2B in the Revolution Medicines deal for daraxonrasib
- The Revolution royalty is tiered and drops to zero above $8B in annual sales, showing sophisticated structuring where both sides optimize for different probability scenarios
- Priority Review Vouchers were created in 2007 to incentivize neglected disease work by offering faster FDA review, but largely failed because even $350M peak value isn't enough to shift pharma portfolios and it rewards approval not patient access
- CVRs create perverse incentives when acquirers must compete against themselves—Sanofi allegedly slow-walked Lemtrada (acquired from Genzyme) while pushing its own competing MS drug Aubagio to minimize $3.8B in CVR payouts
- XOMA pivoted from traditional biotech to buying zombie companies trading below cash value, then selling off their clinical data, patents, and partially completed programs—doubling money on Kinnate acquisition by selling five pipeline assets for $270M
- Concentra Biosciences aggressively forces distressed biotech boards into liquidation by accumulating minority stakes and making offers boards can't refuse without violating fiduciary duty, leading to 84% workforce reduction at Jounce
- The zombie biotech liquidation market is finite, mostly 2020-2021 IPO bubble casualties trading below cash, representing how financial engineering has now colonized even dead and dying companies
- Financialized biotech (BridgeBio, Roivant, royalty-backed programs) represents only ~2% of biotech funding currently, suggesting the market may be self-limiting with finite rare-disease opportunities
- The 2025-2030 patent cliff threatens $300B in revenue (one-sixth of industry annual revenue), 3x larger than 2010s cliffs, potentially pushing Big Pharma toward lower-risk diseases and more synthetic royalty agreements
- The core worry is not that financial engineering is bad, but that it's so legible to capital markets that money flows there exclusively, diminishing institutional capacity to fund illegible, expensive, likely-to-fail biology that occasionally produces revolutionary medicines
Decoder
- Hub-and-spoke model: Corporate structure where a parent holding company creates subsidiary companies, each with separate equity and focused on single drug programs, so individual failures don't kill the parent
- Synthetic royalty: A manufactured financial claim on future drug revenues created specifically to raise capital, not from original licensing agreements—biotech sells percentage of future sales that didn't previously exist as an obligation
- PRV (Priority Review Voucher): Tradable voucher awarded for developing neglected disease treatments that grants faster FDA review (6 months vs 10 months), can be sold on secondary market with prices ranging from $21M to $350M
- CVR (Contingent Value Right): Conditional payment in M&A deals where acquirer pays target shareholders additional amounts if acquired drug hits specified milestones—sometimes structured as tradable securities
- Zombie biotech: Publicly traded biotech company whose stock trades below the cash on its balance sheet, meaning the market values its IP, team, and clinical programs as worse than worthless
- Poison pill: Anti-takeover defense where if acquirer crosses ownership threshold (typically 10%), other shareholders get rights to buy discounted shares, instantly diluting the acquirer's stake
- Patent cliff: Period when many drug patents expire simultaneously, exposing pharmaceutical companies to generic competition and massive revenue loss—2025-2030 cliff threatens $300B
Original article
Finance doesn't really make drug development easier. However, it does make failure more survivable. Financialization is just the process of making implicit economic relationships explicit and tradable. Having more liquid markets for biotech risk is almost certainly better than having fewer. The industry being willing to fund biology that's expensive and likely to fail could result in more discoveries that change the world.